2020 Q1 Form 10-Q Financial Statement
#000156459020024168 Filed on May 11, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $165.0K | $5.000K |
| YoY Change | 3200.0% | 0.0% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $9.493M | $6.040M |
| YoY Change | 57.17% | -58.06% |
| % of Gross Profit | ||
| Research & Development | $27.37M | $11.70M |
| YoY Change | 133.97% | -11.96% |
| % of Gross Profit | ||
| Depreciation & Amortization | $3.500M | $2.395M |
| YoY Change | 46.14% | 47.57% |
| % of Gross Profit | ||
| Operating Expenses | $18.61M | $18.34M |
| YoY Change | 1.46% | -35.17% |
| Operating Profit | -$36.70M | -$18.34M |
| YoY Change | 100.17% | -35.18% |
| Interest Expense | $1.889M | $410.0K |
| YoY Change | 360.73% | 1142.42% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$707.0K | $47.00K |
| YoY Change | -1604.26% | -92.67% |
| Pretax Income | -$37.41M | -$17.92M |
| YoY Change | 108.75% | -35.17% |
| Income Tax | $18.00K | -$36.00K |
| % Of Pretax Income | ||
| Net Earnings | -$18.38M | -$17.89M |
| YoY Change | 2.78% | -35.01% |
| Net Earnings / Revenue | -11141.21% | -357700.0% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$99.57K | -$220.2K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 79.09M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $40.20M | $98.55M |
| YoY Change | -59.21% | -19.09% |
| Cash & Equivalents | $58.65M | $22.28M |
| Short-Term Investments | $23.30M | $76.27M |
| Other Short-Term Assets | $78.00K | $80.00K |
| YoY Change | -2.5% | -75.61% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $44.10M | $113.4M |
| YoY Change | -61.12% | -10.54% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $69.60M | $67.92M |
| YoY Change | 2.47% | -11.56% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | $0.00 | |
| YoY Change | ||
| Long-Term Investments | $9.300M | $13.40M |
| YoY Change | -30.6% | 57.65% |
| Other Assets | $4.100M | $314.0K |
| YoY Change | 1205.73% | -21.5% |
| Total Long-Term Assets | $82.90M | $94.83M |
| YoY Change | -12.58% | -7.93% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $44.10M | $113.4M |
| Total Long-Term Assets | $82.90M | $94.83M |
| Total Assets | $127.0M | $208.3M |
| YoY Change | -39.02% | -9.37% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $3.100M | $2.804M |
| YoY Change | 10.56% | -22.11% |
| Accrued Expenses | $9.800M | $20.24M |
| YoY Change | -51.59% | 67.29% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $100.0K | |
| YoY Change | -66.67% | |
| Total Short-Term Liabilities | $14.25M | $27.70M |
| YoY Change | -48.57% | 42.79% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | -100.0% | |
| Other Long-Term Liabilities | $10.20M | $12.80M |
| YoY Change | -20.31% | 58.02% |
| Total Long-Term Liabilities | $10.20M | $12.80M |
| YoY Change | -20.31% | 30.61% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $14.25M | $27.70M |
| Total Long-Term Liabilities | $10.20M | $12.80M |
| Total Liabilities | $24.43M | $40.50M |
| YoY Change | -39.68% | 37.29% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$680.6M | |
| YoY Change | ||
| Common Stock | $783.3M | |
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $102.6M | $167.8M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $127.0M | $208.3M |
| YoY Change | -39.02% | -9.36% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$18.38M | -$17.89M |
| YoY Change | 2.78% | -35.01% |
| Depreciation, Depletion And Amortization | $3.500M | $2.395M |
| YoY Change | 46.14% | 47.57% |
| Cash From Operating Activities | -$31.11M | -$13.08M |
| YoY Change | 137.86% | -15.69% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $315.0K | $2.104M |
| YoY Change | -85.03% | -57.08% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $14.31M | -$17.36M |
| YoY Change | -182.43% | -321.99% |
| Cash From Investing Activities | $13.99M | -$19.46M |
| YoY Change | -171.92% | -766.4% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -123.0K | 39.20M |
| YoY Change | -100.31% | -46211.76% |
| NET CHANGE | ||
| Cash From Operating Activities | -31.11M | -13.08M |
| Cash From Investing Activities | 13.99M | -19.46M |
| Cash From Financing Activities | -123.0K | 39.20M |
| Net Change In Cash | -17.15M | 6.658M |
| YoY Change | -357.54% | -152.52% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$31.11M | -$13.08M |
| Capital Expenditures | $315.0K | $2.104M |
| Free Cash Flow | -$31.42M | -$15.18M |
| YoY Change | 106.97% | -25.63% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
-1000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
7000 | |
| CY2019Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
3000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.19 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.22 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
|
-24000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
|
61000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
0 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-23000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
61000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
445000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
-123000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
146006000 | |
| CY2020Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-128000 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
10000 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
127023000 | |
| CY2020Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3613000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
3981000 | |
| CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14248000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
11559000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10180000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10885000 | |
| CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
24428000 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
783287000 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-680574000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
102595000 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
98498432 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
98498432 | |
| CY2020Q1 | us-gaap |
Revenues
Revenues
|
21000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
167808000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1351000 | |
| CY2019Q1 | us-gaap |
Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
|
35151000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
4070000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
-26000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-18383000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-17885000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2217000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
2395000 | |
| CY2020Q1 | nk |
Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
|
674000 | |
| CY2019Q1 | nk |
Operating Lease Right Of Use Asset Non Cash Lease Expense
OperatingLeaseRightOfUseAssetNonCashLeaseExpense
|
624000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
445000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1351000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-45000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-41000 | |
| CY2020Q1 | nk |
Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
|
-17000 | |
| CY2019Q1 | nk |
Non Cash Interest Income Expense From Operating Activities
NonCashInterestIncomeExpenseFromOperatingActivities
|
95000 | |
| CY2020Q1 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
-1000 | |
| CY2019Q1 | us-gaap |
Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-244000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-80000 | |
| CY2020Q1 | nk |
Increase Decrease In Operating Lease Right Of Use Asset Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet
|
0 | |
| CY2019Q1 | nk |
Increase Decrease In Operating Lease Right Of Use Asset Net
IncreaseDecreaseInOperatingLeaseRightOfUseAssetNet
|
247000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-335000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-8000 | |
| CY2020Q1 | nk |
Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
|
1270000 | |
| CY2019Q1 | nk |
Increase Decrease In Accounts Payable Current
IncreaseDecreaseInAccountsPayableCurrent
|
670000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
997000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
|
797000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
300000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
-162000 | |
| CY2020Q1 | nk |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-758000 | |
| CY2019Q1 | nk |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-655000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12596000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-13078000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
146000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2104000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
10300000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
50273000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
32918000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
14163000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-19459000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
0 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
39221000 | |
| CY2020Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
123000 | |
| CY2019Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
26000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-123000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
39195000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
1444000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
6658000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
15687000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
17000000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
17131000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
23658000 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
22279000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
179000 | |
| CY2019Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
1379000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
7000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
3000 | |
| CY2020Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | |
| CY2019Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
0 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
182000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2031000 | |
| CY2020Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
0 | |
| CY2019Q1 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
751000 | |
| CY2020Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-23000 | |
| CY2019Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
118000 | |
| CY2020Q1 | us-gaap |
Stock Issued1
StockIssued1
|
0 | |
| CY2019Q1 | us-gaap |
Stock Issued1
StockIssued1
|
29000 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the recent coronavirus disease (COVID‑19) could have on our significant accounting estimates. Actual results could differ from those estimates.</p> | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents and marketable debt securities.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S. and one in Korea.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the U.S. Food and Drug Administration, or FDA, or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p> | |
| CY2020Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
288000 | |
| CY2020Q1 | nk |
Prepaid Equipment Maintenance
PrepaidEquipmentMaintenance
|
262000 | |
| CY2020Q1 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
205000 | |
| CY2019Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
222000 | |
| CY2019Q4 | nk |
Prepaid License Fees
PrepaidLicenseFees
|
78000 | |
| CY2019 | us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
39200000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5609478 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5328886 | |
| CY2020Q1 | nk |
Prepaid Preclinical And Clinical Trial Services With Related Party
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
|
1249000 | |
| CY2019Q4 | nk |
Prepaid Preclinical And Clinical Trial Services With Related Party
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
|
1021000 | |
| CY2020Q1 | nk |
Prepaid Supplies With Related Party
PrepaidSuppliesWithRelatedParty
|
410000 | |
| CY2019Q4 | nk |
Prepaid Supplies With Related Party
PrepaidSuppliesWithRelatedParty
|
467000 | |
| CY2020Q1 | us-gaap |
Prepaid Rent
PrepaidRent
|
393000 | |
| CY2019Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
392000 | |
| CY2020Q1 | nk |
Insurance Premium Financing Asset
InsurancePremiumFinancingAsset
|
381000 | |
| CY2019Q4 | nk |
Insurance Premium Financing Asset
InsurancePremiumFinancingAsset
|
757000 | |
| CY2020Q1 | nk |
Prepaid Services
PrepaidServices
|
344000 | |
| CY2019Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
372000 | |
| CY2020Q1 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
114000 | |
| CY2019Q4 | us-gaap |
Due From Related Parties Current
DueFromRelatedPartiesCurrent
|
47000 | |
| CY2020Q1 | us-gaap |
Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
|
29000 | |
| CY2019Q4 | us-gaap |
Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
|
34000 | |
| CY2020Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
78000 | |
| CY2019Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
24000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
79108000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
18607000 | |
| CY2020Q1 | nk |
Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
|
3739000 | |
| CY2019Q4 | nk |
Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets
PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
|
4075000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
179000 | |
| CY2019Q4 | nk |
Prepaid Equipment Maintenance
PrepaidEquipmentMaintenance
|
251000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
79363000 | |
| CY2020Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
20824000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
2200000 | |
| CY2019Q1 | us-gaap |
Depreciation
Depreciation
|
1800000 | |
| CY2020Q1 | nk |
Accrued Franchise Sales Use And Property Taxes
AccruedFranchiseSalesUseAndPropertyTaxes
|
168000 | |
| CY2019Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1064000 | |
| CY2020Q1 | nk |
Accrued Laboratory Equipment Supplies And Related Services
AccruedLaboratoryEquipmentSuppliesAndRelatedServices
|
559000 | |
| CY2020Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
1631000 | |
| CY2019Q4 | nk |
Accrued Laboratory Equipment Supplies And Related Services
AccruedLaboratoryEquipmentSuppliesAndRelatedServices
|
640000 | |
| CY2020Q1 | nk |
Accrued Preclinical And Clinical Trial Costs
AccruedPreclinicalAndClinicalTrialCosts
|
511000 | |
| CY2019Q4 | nk |
Accrued Preclinical And Clinical Trial Costs
AccruedPreclinicalAndClinicalTrialCosts
|
281000 | |
| CY2020Q1 | nk |
Available For Sale Securities Debt Securities Period
AvailableForSaleSecuritiesDebtSecuritiesPeriod
|
P2M12D | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
37642000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
10000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
11000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
37641000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
19504000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
30000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
0 | |
| CY2019Q4 | nk |
Accrued Franchise Sales Use And Property Taxes
AccruedFranchiseSalesUseAndPropertyTaxes
|
200000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3154000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3206000 | |
| CY2020Q1 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
78000 | |
| CY2019Q4 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
18000 | |
| CY2020Q1 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
-1000 | |
| CY2019Q1 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
0 | |
| CY2020Q1 | us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
0 | |
| CY2019Q1 | us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
0 | |
| CY2017Q1 | us-gaap |
Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
|
8500000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
0 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
11021000 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
3000 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
4245000 | |
| CY2019Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
8000 | |
| CY2020Q1 | us-gaap |
Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
|
12000000 | |
| CY2019Q3 | us-gaap |
Legal Fees
LegalFees
|
500000 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y3M18D | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y6M | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.09 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.09 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1000000 | |
| CY2019Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1300000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
3221000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3754000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3671000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
2545000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1083000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
1730000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
16004000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2671000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
13333000 | |
| CY2020Q1 | nk |
Operating Lease Payments Related To Options To Extend Lease Terms
OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms
|
3300000 | |
| CY2015Q4 | us-gaap |
Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
|
50000000 | |
| CY2019Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
35200000 | |
| CY2020Q1 | us-gaap |
Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
|
0 | |
| CY2020Q1 | us-gaap |
Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
|
18300000 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
445000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1351000 | |
| CY2019Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
0 | |
| CY2020Q1 | nk |
Class Of Warrant Or Rights Issued
ClassOfWarrantOrRightsIssued
|
0 | |
| CY2019Q1 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2019Q1 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.00 | |
| CY2019Q1 | us-gaap |
Other Tax Expense Benefit
OtherTaxExpenseBenefit
|
-36000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
-100000 |
